Phase 3 study of either ivosidenib monotherapy or azacitidine monotherapy in patients with IDH1-mutant myelodysplastic syndromes who are hypomethylating agent naive (PyramIDH).

Authors: Valeria Santini, Marie Sébert, David Valcárcel, Uma Borate, Weishi Yuan, Stephanie M. Kapsalis, Lorene Simonot, Prapti Arvind Patel, Guillermo Garcia-Manero

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps6584

Source: Full article

---

Abstract

TPS6584